GBT 440

Drug Profile

GBT 440

Alternative Names: GBT440; GTx-011

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Global Blood Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Sickle haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 04 Dec 2016 Phase-III clinical trials in Sickle cell anaemia in USA (PO)
  • 04 Dec 2016 Efficacy and safety data from a phase I/II trial in Sickle cell disease presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 04 Dec 2016 Pharmacokinetics data from a phase I trial (Healthy male volunteers) in Sickle cell disease presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top